Skip to content

Clinical trials

Phase 3 Lung Diseases trials in Canada

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Lung Diseases Phase: Phase 3 Country / region: Canada Clear all

29 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20071
20092
20102
20131
20144
20153
20163
20171
20194
20221
20232
20243
20251

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed18
Recruiting6
Active, not recruiting2
Enrolling by invitation1
Terminated1
Unknown status1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
AstraZeneca11
Novartis Pharmaceuticals2
United Therapeutics2
Vertex Pharmaceuticals Incorporated2
Daiichi Sankyo1
Eli Lilly and Company1
GlaxoSmithKline1
National Heart, Lung, and Blood Institute (NHLBI)1
Nova Scotia Health Authority1
Nuvalent Inc.1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Lung Diseases29
Respiratory Tract Diseases18
Bronchial Diseases10
Asthma9
Lung Diseases, Obstructive9
Carcinoma, Non-Small-Cell Lung5
Lung Neoplasms4
Pathologic Processes4
COVID-193
Connective Tissue Diseases3

Trials

Showing 1 to 25 of 29. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.